Outbreak of Vancomycin-, Ampicillin-, and Aminoglycoside- Resistant Enterococcus faecium Bacteremia in an Adult Oncology Unit
|
|
- Isaac Thornton
- 6 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 1994, p /94/$4.+ Copyright X) 1994, American Society for Microbiology Vol. 38, No. 6 Outbreak of Vancomycin-, Ampicillin-, and Aminoglycoside- Resistant Enterococcus faecium Bacteremia in an Adult Oncology Unit MARISA A. MONTECALVO,l* HAROLD HOROWITZ,1 CHERYL GEDRIS,2 CAROL CARBONARO,2 FRED C. TENOVER,3 ABDUL ISSAH,1 PERRY COOK,4 AND GARY P. WORMSER' Divisions of Infectious Diseases' and Oncology,4 Department of Medicine, and Department of Clinical Pathology, 2 Westchester County Medical Center, Valhalla, New York; and the Hospital Infection Program, Centers for Disease Control and Prevention, Atlanta, Georgia3 Received 7 December 1993/Returned for modification 7 February 1994/Accepted 4 April 1994 An outbreak of bacteremia caused by Enterococcusfaecium with high-level resistance to vancomycin (MIC of >256,ig/ml), ampicillin (MIC of.64,ug/ml), and gentamicin or streptomycin (MIC of.2,,ug/ml) occurred in an adult oncology unit from June 1991 to May Active surveillance for the presence of this organism in stool or perianal cultures was begun in September Between June 1991 and May 1992, seven patients with bacteremia and 22 noninfected carriers of the organism in stool were identified. The vana gene, tested for by PCR and gene probe, was present in all isolates evaluated. All bacteremic patients also had resistant E. faecium present in a stool or perianal culture; the stool isolates tested were closely related to the respective blood isolates as determined by pulsed-field gel electrophoresis. Antibiotic regimens using high-dose ampicillin and an aminoglycoside were ineffective with four patients. Five patients (71%) had multiple positive blood cultures; four of these patients died. Following a multiple logistic regression analysis, it was found that bacteremic patients received a significantly greater number of total antibiotic days compared with noninfected stool carriers (P =.19). The emergence of E. faecium with high-level resistance to vancomycin, ampicillin, and aminoglycosides underscores the importance of performing susceptibility testing on all clinically significant isolates. In the neutropenic adult oncology patient, bacteremia with this organism is of probable gastrointestinal origin, is often persistent, and is refractory to treatment with ampicillin in combination with an aminoglycoside. Prolonged use of antibiotics may predispose patients with gastrointestinal colonization to develop bacteremia. Enterococci are the third-most-common cause of hospitalacquired bacteremia (29), and at some centers they account for up to 5% of bacteremias that occur in neutropenic patients receiving broad-spectrum antibiotics (2, 25). Over the past 2 years there has been a progressive increase in antimicrobial resistance among enterococci (3, 4, 8, 11, 2). With the emergence of vancomycin resistance in 1986 (15, 3), enterococci can now be multiply resistant to all currently approved antimicrobial agents (5, 9, 1, 14-16, 26). This presents a major therapeutic challenge for clinicians. We report an outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium (VAAREF) bacteremia in an adult oncology unit. These infections were refractory to antibiotic treatment and resulted in high mortality. Risk factors which may predispose carriers of VAAREF in stool to develop bacteremia were evaluated. MATERIALS AND METHODS Patient population. Westchester County Medical Center is a 65-bed tertiary care teaching hospital. The adult oncology unit is an 11-room, 22-bed discrete geographic area for patients hospitalized with leukemia, lymphoma, or solid tumors. Vancomycin-resistant E. faecium was first recognized at our center in May Active surveillance and control measures were instituted for the oncology unit beginning 1 September * Corresponding author. Mailing address: Division of Infectious Diseases, Westchester County Medical Center, Macy Pavilion 29SE, Valhalla, NY Phone: (914) Fax: (914) , after 3 patients who had vancomycin-resistant E. faecium bacteremia were identified. Surveillance stool cultures were requested weekly for all patients hospitalized in the unit. Beginning in December 1991, perianal cultures were obtained when stool samples were not available. Perianal cultures were obtained by gently swabbing the perianal skin in a circular manner with a rayon-tipped swab moistened in nonbacteriostatic sterile saline. Swabs were transported to the laboratory in Amies media (Difco, Surrey, United Kingdom). Colonized or infected patients were placed on contact isolation. Cohorting was allowed. Body substance isolation, which included stool precautions (17), was already in use for all patients in the unit. The outbreak was considered over on 8 May 1992, 11 weeks after the last time a patient had bacteremia and after there had been two consecutive weeks in which 1% of the patients hospitalized in the unit had stool or perianal cultures done and no stool carriers were identified. Hospital records of bacteremic patients and stool carriers were reviewed retrospectively. Microbiologic methods. Blood isolates were subcultured from Bactec medium NR6A/7A (Becton Dickinson, Towson, Md.) onto Trypticase soy agar containing 5% sheep blood (TSBA) (BBL, Cockeysville, Md.). Stool or perianal swab samples were plated onto Columbia CNA agar containing 5% sheep blood and incubated at 35 C for 24 h. Beginning 1 January 1992, samples were also plated onto enterococcus agar (Difco, Detroit, Mich.) supplemented with 5 plg of vancomycin per ml. On the basis of the growth observed, at least five isolates with colonial morphology consistent with enterococci were selected at random from either medium. A lawn of each was spread onto TSBA, incubated at 35 C for 24 h, and 1363
2 1364 MONTECALVO ET AL. screened for vancomycin-resistant colonies by using a 3-,ig vancomycin disk. Identification of isolates from blood, stool, and perianal cultures as E. faecium was based upon standard techniques (7). Resistance to vancomycin (MIC of >16,ug/ml) and ampicillin (MIC of >8,ug/ml) and high-level resistance to gentamicin or streptomycin (MIC of >2,,ug/ml) were determined initially by using the MicroScan Positive MIC Type 6 susceptibility panel (Baxter Diagnostics, Inc., W. Sacramento, Calif.) according to the National Committee for Clinical Laboratory Standards guidelines (24). P-lactamase production was assayed by using a nitrocefin disk (Cefinase; BBL). MICs of penicillin, ampicillin, vancomycin, teicoplanin (Merrell Dow Pharmaceuticals, Inc., Cincinnati, Ohio), gentamicin, and streptomycin were determined by broth macrodilution and microdilution methods (23, 28). To detect the presence of the vana resistance determinant in the enterococcal isolates, a PCR assay and a vana gene probe were used as previously described (6). Pulsed-field gel electrophoresis (PFGE) was performed to determine the molecular relatedness of six blood isolates and three stool isolates from five bacteremic patients and of three stool isolates from three nonbacteremic stool carriers. Organisms were lysed as previously described (6), and the DNA was digested in situ with the restriction endonuclease SmaI (GIBCO Bethesda Research Laboratories). Electrophoresis and gel interpretation were performed as described by Murray et al. (21, 22). Control strains were E. faecium A256, E. faecium D366, Enterococcus faecalis V583, E. faecium 228, and Enterococcus gallinarum CDC-NJ4. Definitions. Bacteremia was defined as the presence of VAAREF in at least 1 blood culture. Stool carriers were defined as patients with VAAREF present in stool or perianal culture but who manifested no evidence of infection with this organism during the entire period of their hospitalization. Neutropenia was defined as an absolute neutrophil count of '19 neutrophils per liter, and fever was defined as an oral temperature of.1.4f. Antibiotic treatment is described in terms of "duration of antibiotic therapy," which is defined as the number of days a patient received at least one intravenous antibiotic, and "total antibiotic days," which is defined as the summation of the numbers of days each antibiotic was given. Statistical analysis. Differences for continuous variables were analyzed by using a Wilcoxon rank sum test. Differences for categorical variables were analyzed by using Fisher's exact test or chi-square analysis. A multiple logistic regression analysis was performed to determine the best subset of variables that predicted only VAAREF bowel colonization and not bacteremia with this organism. Odds ratios and exact 95% confidence intervals were computed by using regression coefficients. All P values are results of two-tailed tests performed at type I error of.5 (12, 31). RESULTS The outbreak Seven (1.7%) of the 413 oncology patients hospitalized in the unit from 1 June 1991, the day the first patient developed bacteremia, until 8 May 1992, the day the outbreak was considered over, developed VAAREF bacteremia (Fig. 1). During the period of active surveillance, 1 September 1991 to 8 May 1992, stool or perianal cultures were obtained from 167 (48%) of the 347 nonbacteremic patients hospitalized in the unit and 22 (13%) of the 167 patients were identified as stool carriers. Blood cultures were obtained from 15 (68%) of the stool carriers while they were neutropenic and -E X 2 2 ~'5.T 'a15- IO- U 25T a. 5- D c ANTiMICROB. AGENTS CHEMOTHER. 1 _O * * June July Aug Sept Oct Nov Dec Jan Feb Mar Apr May +t MONTHS FIG. 1. Incidence of new patients (number) with VAAREF bacteremia per month and prevalence of noninfected stool carriers (percent) per month in the adult oncology unit from 1 June 1991 until 8 May The arrow indicates the beginning of active surveillance in the unit. after VAAREF had been identified in a stool or perianal culture, but none of the blood cultures grew VAAREF. Antibiotic resistance patterns of E. faecium. The E. faecium blood and stool isolates from the seven bacteremic patients and the stool or perianal isolates from the 22 stool carriers were resistant to vancomycin and ampicillin and had high-level gentamicin or streptomycin resistance as indicated by the MicroScan susceptibility panel. MICs were determined for E. faecium blood and stool isolates in the case of three bacteremic patients, for blood isolates only in the case of two bacteremic patients, for stool isolates only in the case of two bacteremic patients, and for stool or perianal isolates in the case of 18 of 22 stool carriers. MICs of vancomycin were between 256 and 512,ug/ml, MICs of teicoplanin were between 32 and 512,ig/ml, MICs of ampicillin were between 64 and 128,ug/ml, MICs of penicillin were >256,ug/ml, and high-level resistance to gentamicin (MIC of >2,,ug/ml) was present in 6 of 7 isolates (86%) from bacteremic patients and in 12 of 18 isolates (67%) from stool carriers. High-level resistance to streptomycin (MIC of >2,,ug/ml) was present in 5 of 7 isolates (71%) from bacteremic patients and in 16 of 18 isolates (88%) from stool carriers. None of the isolates produced 1-lactamase. The presence of the vana gene in 5 blood isolates and 3 stool or perianal isolates tested was confirmed by using a PCR assay and a vana gene probe specific for this resistance determinant. Clinical features of bacteremic patients. Five patients had acute leukemia, one had lymphoblastic lymphoma, and one had chronic myelogenous leukemia with lymphoblastic transformation. At the time of VAAREF bacteremia these seven patients had been hospitalized for a median of 24 days (range, 15 to 52 days) and had had neutropenia due to chemotherapy or persistent leukemia for a median of 24 days (range, 9 to 52 days). On the day of the initial positive blood culture for VAAREF all seven patients had fever. The source of infection was not apparent for any of the seven patients. Urine cultures were sterile for two of the patients; urinalyses were normal for four. None of the patients showed definite evidence of an intraab-
3 VOL. 38, 1994 OUTBREAK OF VANCOMYCIN-RESISTANT E. FAECIUM BACTEREMIA 1365 CO) 5 4, EZZII+II+ Death A,A Death Death A,T/A,A A,G/A,A Ez- 1 A,T t Survived Death kb I~~~~~~~~~~~~~~~~~~ TIME IN DAYS FIG. 2. Days on which VAAREF was present (+) in blood culture or absent (-) from blood culture beginning on the day of the first positive blood culture (day 1) and continuing until death or discharge of the five patients with multiple positive blood cultures. The arrow indicates the resolution of neutropenia, which only occurred in patient 2. The boxes indicate the time periods in which the patients were receiving ampicillin plus an aminoglycoside. A, G, ampicillin plus gentamicin; A, T, ampicillin plus tobramycin; A, A, ampicillin plus amikacin. FIG. 3. PFGE of E. faecium stool (S) and blood (B) isolates from three bacteremic patients (1, 3, and 4), blood isolates only from two bacteremic patients (2 and 5), and stool isolates from three nonbacteremic stool carriers (SCI, SC2, and SC3). Lanes from left to right are stool and blood isolates from patient 1 (Si and B1), stool and blood isolates from patient 3 (S3 and B3), stool and blood isolates from patient 4 (S4 and B4), a blood isolate from patient 5 (B5), blood isolates from patient 2 (B2R and B2s), and stool isolates from nonbacteremic stool carriers (SC1, SC2, and SC3). The molecular size standard is lambda concatemer. dominal infection. All 7 patients had a central venous catheter in place at the time of bacteremia, but none had pain or erythema at the insertion site. Catheter tip cultures, performed by using the roll plate technique of Maki et al. (18), were negative for four patients. VAAREF was present in a sputum culture of one patient. This was considered to represent colonization because a sputum Gram stain showed no organisms and the patient's respiratory status was improving. None of the patients had clinical signs of endocarditis; one patient had a normal transthoracic echocardiogram. All seven bacteremic patients had VAAREF present in a stool or perianal culture. VAAREF were detected in stool or perianal culture either prior to (by 18, 7, or 7 days) the day of the first positive blood culture, on the day of the first positive blood culture, or following (by 4, by 4, or 11 days) the day of the first positive blood culture. None of these last three patients had stool or perianal cultures performed prior to or on the day of the first positive blood culture. Three patients had polymicrobic bacteremia, including one patient who was infected by two strains of E. faecium. This patient had a VAAREF strain with high-level gentamicin resistance and a strain of E. faecium that was only resistant to ampicillin (MIC of 128,ug/ml). Five patients had multiple positive blood cultures for VAAREF over periods ranging from 7 to 63 days. Four of these patients died during their hospitalization, all of whom remained neutropenic because of persistent leukemia and had positive blood cultures for VAAREF just prior to death (Fig. 2). Two of the patients who died had a recurrence of VAAREF bacteremia after having had multiple negative blood cultures for VAAREF over periods of 56 days and 13 days, respectively. Of note, one patient with a recurrence of bacteremia (Fig. 2, patient 1) had VAAREF present in five of six stool cultures obtained during the 6 weeks in which the blood cultures were sterile. The three patients who survived all had their neutropenia resolve during the period of their hospitalization (9 to 3 days following the first blood culture with VAAREF). Two of the surviving patients had VAAREF present in only one blood culture; each of these patients had two subsequent blood cultures without VAAREF. The other patient had VAAREF present in five of seven blood cultures obtained over a 9-day period, but during the subsequent 1 days, while neutropenia was resolving, another seven blood cultures were sterile (Fig. 2, patient 2). High-dose ampicillin (2 g every 4 h) plus an aminoglycoside was given to five patients. Ampicillin was used with these patients because at the time only the susceptibility determined by the MicroScan system (MIC of >8,ug/ml) was known. Since the organisms did not produce 1-lactamase, it was expected that the MIC of ampicillin for the organisms would be between 16 and 32,ug/ml, as is usually the case for E. faecium (19, 2), and therefore high-dose ampicillin could have some activity against the organism. One patient was not treated, because she was improving clinically, and another patient died prior to receiving ampicillin. Of the five patients who received ampicillin and an aminoglycoside, four had VAAREF bacteremia either during treatment with the ampicillin-containing regimen or after ampicillin treatment was discontinued (Fig. 2, patients 1, 2, 3, and 5). The other patient had VAAREF in only a single blood culture and did not have VAAREF isolated from any subsequent blood cultures either during or following treatment with ampicillin and an aminoglycoside. PFGE indicated that the VAAREF isolates from the stool (S) and blood (B) of patient 1 (Si and B1) (Fig. 3) were identical, while the paired stool and blood isolates from patient 3 (S3 and B3) were closely related, differing by only a single band. The stool and blood isolates from patient 4 (S4 and B4) also were closely related, differing by a single band, but one different from that which differed in the isolates from patient 3 (S3 and B3). The stool and blood isolates from patients 3 (S3 and B3) and 4 (S4 and B4) were also highly related to one another, to the blood isolate from patient 5 (B5), and to two of the three isolates from nonbacteremic stool carriers (SC1 and SC3) that were analyzed. The two blood isolates from patient 2, (B2R and B2s), one of which was resistant to vancomycin and gentamicin (B2R) and the other of which was susceptible to both drugs (B2s), differed only by the presence of a single additional high-molecular-weight band in the fragment pattern of the vancomycin-resistant isolate (Fig. 3). Bacteremic patients compared with stool carriers. When bacteremic patients at the time of first positive blood culture for VAAREF were compared with noninfected carriers of this organism in the stool at the time of first positive stool or perianal culture, several variables were significantly associated
4 1366 MONTECALVO ET AL. TABLE 1. Characteristics of patients with VAAREF bacteremia compared with those of nonbacteremic stool carriers No. of subjects or value for characteristic Characteristic Bacteremic Stool carriers patients (n = 7) (n = 22) P value Age in years 36 (2-48)a 58.5 (2-8).6 Male 4 (57)b 14 (64) >.5 Race = white 6 (86) 18 (82) >.5 Diagnosis of acute 6 (86) 17 (77) >.5 leukemia Days hospitalized 24 (15-52) 21.5 (4-7).295 Patients 7 (1) 13 (59).66 neutropenic Days neutropenic 24 (9-52) 16 (-64).43 Neutrophil count 2 (1-3) 96 (1-12,741).34 Total antibiotic 84 (47-112) 4.5 (-13).7 days Duration of 24 (16-51) 16.5 (-48).23 antibiotic treatment Intravenous 12 (6-38) 6.5 (-35).55 vancomycin days Ceftazidime days 24 (-37) 1.5 (-35).23 Patients receiving 2 (29) 1 (.5).67 oral vancomycin a Median value for characteristic followed by range in parentheses. b Number of subjects with characteristic followed by percentage in parentheses. with bacteremia by univariate analysis (Table 1). However, following a multiple logistic regression analysis, only total antibiotic days was significantly associated with the development of bacteremia (P =.19). DISCUSSION ANTIMICROB. AGENTS CHEMOTHER. Although enterococci are an increasing cause of infection among oncology patients (2, 13, 25, 27), this is the first report concerning adult oncology patients in which the organisms were resistant to vancomycin, ampicillin, and aminoglycosides and the first to document persistent or relapsing bacteremia. The patient's endogenous gastrointestinal flora appeared to be the reservoir for this organism on the basis of the presence of VAAREF in a stool or perianal skin culture for all bacteremic patients, the presence of an isolate from a stool or perianal skin culture that was nearly identical to the blood isolate for the three patients studied, as determined by PFGE, and the absence of an identifiable alternative source of infection. The presence of multiple positive blood cultures for VAAREF in the case of five patients was a striking and unique feature of our outbreak which was absent from other reports of VAAREF infections (9, 1, 14, 16). Sustained neutropenia due to leukemia was likely an important factor contributing to the bacteremia. Although the pattern of bacteremia raised concern about a possible endovascular site of infection, none was apparent clinically. The lack of a bactericidal regimen for the treatment of VAAREF may have also contributed to the persistence of bacteremia. Since there is currently no clearly effective antimicrobial therapy for VAAREF bacteremia, with neutropenic patients the use of colony-stimulating factors or granulocyte transfusions (1) should be considered a possible therapeutic option. Twenty-two patients were found to be stool carriers. We suspect that this may be an underestimate of the actual number of stool carriers because surveillance cultures were only obtained one day per week, a selective medium for primary isolation of the organism was not initially used, and only 48% of the nonbacteremic patients had stool or perianal cultures done. By obtaining stool or perianal cultures on one day each week, we also may have selected for stool carriers who were hospitalized for at least 7 days. Since even among this highly vulnerable group of oncology patients the majority of patients from whom VAAREF was isolated were noninfected stool carriers, we examined variables that may have predisposed stool carriers to develop bacteremia. Following a multiple logistic regression analysis, only total antibiotic days was significantly associated with bacteremia. We hypothesize that in the neutropenic leukemia or lymphoma patient, the more prolonged the use of multiple antibiotics, the greater the selective pressure on the bowel flora which may promote the growth of large numbers of resistant E. faecium organisms. Particularly in the setting of an intestinal epithelium damaged because of chemotherapy, this selective pressure on the bowel flora may result in a greater propensity to develop bacteremia. Factors associated with transmission and control of VAAREF were not studied during this outbreak. The PFGE indicated that the isolates had closely related genetic material and were likely to be clonally related (21, 22). We suspect, as others have (1, 14, 16, 26), that the use of contact isolation measures may have contributed to the control of the outbreak. However, the efficacy of contact isolation as a measure to reduce or eliminate the spread of this organism needs to be established. ACKNOWLEDGMENTS We thank Bertha Hill of the Hospital Infection Program, Centers for Disease Control and Prevention, who performed antimicrobial susceptibility testing; Barbara Schable of the Hospital Infection Program, Centers for Disease Control and Prevention, who performed the PFGE; M. Sung Lee, Robert Nadelman, and John Nowakowski of the Division of Infectious Diseases, Westchester County Medical Center, and Ken Van Horn of the Department of Clinical Pathology, Westchester County Medical Center, for their assistance in recognizing and managing this outbreak. Barbara Moreland provided secretarial assistance. REFERENCES 1. Alavi, J. B., R. K. Root, I. Djerassi, A. E. Evans, S. J. Gluckman, R R. MacGregor, D. Guerry, A. D. Schreiber, J. M. Shaw, P. Koch, and R. A. Cooper A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N. Engl. J. Med. 296: Awada, A., P. VanderAuwera, F. Meunier, D. Daneau, and J. Klastersky Streptococcal and enterococcal bacteremia in patients with cancer. Clin. Infect. Dis. 15: Bush, L M., J. Calmon, C. L Cherney, M. Wendeler, P. Pitsakis, J. Poupard, M. E. Levison, and C. C. Johnson High level penicillin resistance among isolates of enterococci. Implications for treatment of enterococcal infections. Ann. Intern. Med. 11: Calderwood, S. A., C. Wennersten, R C. Moellering, Jr., L. J. Kunz, and D. J. Krogstad Resistance to six aminoglycosidic aminocyclitol antibiotics among enterococci: prevalence, evolution, and relationship to synergism with penicillin. Antimicrob. Agents Chemother. 12: Centers for Disease Control and Prevention Nosocomial enterococci resistant to vancomycin-united States, Morbid. Mortal. Weekly Rep. 42: Clark, N. C., R C. Cooksey, B. C. Hill, J. M. Swenson, and F. C. Tenover Characterization of glycopeptide-resistant enterococci from U.S. hospitals. Antimicrob. Agents Chemother. 37: Facklam, R. R, and J. A. Washington II Streptococcus and related catalase-negative gram-positive cocci, p In Balows, A. W. J. Hausler, Jr., K. L. Herrmann, H. D. Isenberg, and
5 VOL. 38, 1994 OUTBREAK OF VANCOMYCIN-RESISTANT E. FAECIUM BACTEREMIA 1367 H. J. Shadomy (ed.), Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, D.C. 8. Grayson, M. L., G. M. Eliopoulos, C. B. Wennerstein, K. L. Ruoff, P. C. De Girolami, M. J. Ferraro, and R. C. Moellering, Jr Increasing resistance to P-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob. Agents Chemother. 35: Handwerger, S., D. C. Perlman, D. Altarac, and V. McAuliffe Concomitant high-level vancomycin and penicillin resistance in clinical isolates of enterococci. Clin. Infect. Dis. 14: Handwerger, S., B. Raucher, D. Altarac, J. Monka, S. Marchione, K. V. Singh, B. E. Murray, J. Wolf, and B. Walters Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin and gentamicin. Clin. Infect. Dis. 16: Horodniceanu, T., T. Bougueleret, N. El-Solh, G. Bieth, and F. Delbos High-level, plasmid-bome resistance to gentamicin in Streptococcus faecalis subsp. zymogenes. Antimicrob. Agents Chemother. 16: Hosmer, D. W., and S. Lemeshow Applied logistic regression. John Wiley and Sons, New York. 13. Karp, J. E., J. D. Dick, C. Angelopulos, P. Charache, L. Green, P. J. Burke, and R. Saral Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized double-blind placebo controlled clinical trial in patients with acute leukemia. Am. J. Med. 81: Karanfil, L. V., M. Murphy, A. Josephson, R Gaynes, L. Mandel, B. C. Hill, and J. M. Swenson A cluster of vancomycinresistant Enterococcus faecium in an intensive care unit. Infect. Control Hosp. Epidemiol. 13: Leclerq, R, E. Derlot, J. Duval, and P. Courvalin Plasmid mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N?. Engl. J. Med. 319: Livornese, L L., Jr., S. Dias, C. Samuel, B. Romanowski, S. Taylor, P. May, P. Pitsakis, G. Woods, D. Kaye, M. E. Levison, and C. C. Johnson Hospital acquired infection with vancomycin resistant Enterococcus faecium transmitted by electric thermometers. Ann. Intern. Med. 117: Lynch, P., M. M. Jackson, M. J. Cummings, and W. E. Stamm Rethinking the role of isolation practices in the prevention of nosocomial infections. Ann. Intern. Med. 17: Maki, D. G., C. E. Weise, and H. W. Sarafin A semiquantitative culture method for identifying intravenous catheter-related infection. N. Engl. J. Med. 296: Moellering, R C., Jr.,. M. Korzeniowski, M. A. Sande, and C. B. Wennersten Species specific resistance to antimicrobial synergism in Streptococcus faecium and Streptococcus faecalis. J. Infect. Dis. 14: Murray, B. E. The life and times of the enterococcus Clin. Microbiol. Rev. 3: Murray, B. E., K. V. Singh, J. D. Heath, B. R. Sharma, and G. M. Weinstock Comparison of genomic DNAs of different enterococcal isolates using restriction endonucleases with infrequent recognition sites. J. Clin. Microbiol. 28: Murray, B. E., K. V. Singh, S. M. Markowitz, H. A. Lopardo, J. E. Patterson, M. J. Zervos, E. Rubeglio, G. M. Eliopoulos, L. B. Rice, F. W. Goldstein, S. G. Jenkins, G. M. Caputo, R. Nasnas, L. S. Moore, E. S. Wong, and G. Weinstock Evidence for clonal spread of a single strain of,b-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states. J. Infect. Dis. 163: Nachamkin, I., P. Axelrod, G. H. Talbot, S. H. Fischer, C. B. Wennersten, R. C. Moellering, Jr., and R R. MacGregor Multiply high-level-aminoglycoside-resistant enterococci isolated from patients in a university hospital. J. Clin. Microbiol. 26: National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 2nd ed. NCCLS document M7-A2. National Committee for Clinical Laboratory Standards, Villanova, Pa. 25. Pizzo, P. A., J. W. Hathorn, J. Hiemenz, M. Browne, J. Commers, D. Cotton, J. Gress, D. Longo, D. Marshall, J. McKnight, M. Rubin, J. Skelton, M. Thaler, and R Wesley A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N. Engl. J. Med. 315: Rubin, L. G., V. Tucci, E. Cercenado, G. Eliopoulos, and H. D. Isenberg Vancomycin-resistant Enterococcus faecium in hospitalized children. Infect. Control Hosp. Epidemiol. 13: Rubin, M., J. W. Hathorn, D. Marshall, J. Gress, S. M. Steinberg, and P. A. Pizzo Gram-positive infections and the use of vancomycin in 55 episodes of fever and neutropenia. Ann. Intern. Med. 18: Sahm, D. F., and J. A. Washington II Antibacterial susceptibility tests: dilution methods, p In A. Balows, W. J. Hausler, Jr., K. L. Herrmann, H. D. Isenberg, and H. J. Shadomy (ed.), Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, D.C. 29. Schaberg, D. R., D. H. Culver, and R P. Gaynes Major trends in the microbial etiology of nosocomial infection. Am. J. Med. 91(3B): Uttley, A. H. C., C. H. Collins, J. Naidoo, and R. C. George Vancomycin-resistant enterococci. Lancet i: (Letter.) 31. Zar, J. H Biostatistical analysis, 2nd ed. Prentice Hall, Englewood Cliffs, N.J.
Agent-Resistant Enterococci
JOURNAL OF CLINICAL MICROBIOLOGY, July 1993, p. 1695-1699 0095-1137/93/071695-05$02.00/0 Copyright 1993, American Society for Microbiology Vol. 31, No. 7 Ability of Clinical Laboratories To Detect Antimicrobial
More informationSusceptibility Testing of Clinical Isolates of Enterococcus faecium
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 1992, p. 41-45 0095-1137/92/010041-05$02.00/0 Copyright 1992, American Society for Microbiology Vol. 30, No. 1 Susceptibility Testing of Clinical Isolates of Enterococcus
More informationAre Clinical Laboratories in California Accurately Reporting Vancomycin-Resistant Enterococci?
JOURNAL OF CLINICAL ROBIOLOGY, Oct. 1997, p. 2526 2530 Vol. 35, No. 10 0095-1137/97/$04.00 0 Copyright 1997, American Society for Microbiology Are Clinical Laboratories in California Accurately Reporting
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationSynergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci
Journal of Antimicrobial Chemotherapy (78) 4, 53-543 Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci Chatrchal Watanakunakoni and Cheryl Glotzbecker Infectious
More informationEpidemiologic Analysis and Genotypic Characterization of a Nosocomial Outbreak of Vancomycin-Resistant Enterococci
JOURNAL OF CLINICAL MICROBIOLOGY, May 1993, p. 1280-1285 0095-1137/93/051280-06$02.00/0 Copyright ) 1993, American Society for Microbiology Vol. 31, No. 5 Epidemiologic Analysis and Genotypic Characterization
More informationORIGINAL INVESTIGATION
Enterococcus faecium Bacteremia Does Vancomycin Resistance Make a Difference? Valentina Stosor, MD; Lance R. eterson, MD; Michael ostelnick, Rh; Gary A. Noskin, MD ORIGINAL INVESTIGATION Background: Enterococcus
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationAntimicrobial Susceptibility of Vancomycin-Resistant Leuconostoc, Pediococcus, and Lactobacillus Species
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 99, p. 53-59 Vol. 3, No. 66-/9/53-7$./ Copyright C 99, American Society for Microbiology Antimicrobial Susceptibility of Vancomycin-Resistant,, and Species J.
More informationGlycopeptide Resistant Enterococci (GRE) Policy IC/292/10
BASINGSTOKE AND NORTH HAMPSHIRE NHS FOUNDATION TRUST Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10 Supersedes: IC/292/07 Owner Name Dr Nicki Hutchinson Job Title Consultant Microbiologist,
More informationFecal Emergence of Vancomycin-Resistant Enterococci after Prophylactic Intravenous Vancomycin
ISPUB.COM The Internet Journal of Infectious Diseases Volume 2 Number 2 Fecal Emergence of Vancomycin-Resistant Enterococci after Prophylactic Intravenous Vancomycin E Nahum, Z Samra, J Ben-Ari, O Dagan,
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More informationENTEROCOCCI. April Abbott Deaconess Health System Evansville, IN
ENTEROCOCCI April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic antimicrobial susceptibility principles and resistance mechanisms for Enterococcus Describe issues surrounding AST
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Doo Ryeon Chung, MD, PhD Professor of Medicine, Division of Infectious Diseases Director, Infection Control Office SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE CASE 1
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationMolecular and clinical epidemiology of vancomycin-resistant Enterococcus faecalis
Journal of Antimicrobial Chemotherapy (2004) 53, 626 630 DOI: 10.1093/jac/dkh138 Advance Access publication 18 February 2004 Molecular and clinical epidemiology of vancomycin-resistant Enterococcus faecalis
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationComparison of Daptomycin, Vancomycin, and Ampicillin-
ANTIMICROBIAL AGENTS AN CHEMOTHERAPY, Sept. 12, p. 1-1 -/2/1-$2./ Copyright C 12, American Society for Microbiology Vol., No. Comparison of aptomycin, Vancomycin, and Ampicillin- Gentamicin for Treatment
More informationDecrease of vancomycin resistance in Enterococcus faecium from bloodstream infections in
AAC Accepted Manuscript Posted Online 30 March 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.00513-15 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 Decrease of vancomycin
More informationEvaluation of the AutoMicrobic System for Susceptibility Testing of Aminoglycosides and Gram-Negative Bacilli
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 1987, p. 546-550 0095-1137/87/030546-05$02.00/0 Copyright C 1987, American Society for Microbiology Vol. 25, No. 3 Evaluation of the AutoMicrobic System for Susceptibility
More informationEvaluation of MicroScan MIC Panels for Detection of
JOURNAL OF CLINICAL MICROBIOLOGY, May 1988, p. 816-820 Vol. 26, No. 5 0095-1137/88/050816-05$02.00/0 Copyright 1988, American Society for Microbiology Evaluation of MicroScan MIC Panels for Detection of
More informationDuke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients
Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients PURPOSE Fever among neutropenic patients is common and a significant cause of morbidity
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationOpen Access. The Open Microbiology Journal, 2008, 2,
The Open Microbiology Journal, 2008, 2, 79-84 79 Open Access In vitro Antimicrobial Activity of Ampicillin-Ceftriaxone and Ampicillin- Ertapenem Combinations Against Clinical Isolates of Enterococcus faecalis
More informationORIGINAL INVESTIGATION. The Role of Colonization Pressure in the Spread of Vancomycin-Resistant Enterococci
The Role of Colonization Pressure in the Spread of Vancomycin-Resistant Enterococci An Important Infection Control Variable ORIGINAL INVESTIGATION Marc J. M. Bonten, MD; Sarah Slaughter, MD; Anton W. Ambergen;
More informationAntimicrobial Resistance Surveillance from sentinel public hospitals, South Africa, 2013
Antimicrobial Resistance Surveillance from sentinel public s, South Africa, 213 Authors: Olga Perovic 1,2, Melony Fortuin-de Smidt 1, and Verushka Chetty 1 1 National Institute for Communicable Diseases
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationMICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,
More informationSource: Portland State University Population Research Center (
Methicillin Resistant Staphylococcus aureus (MRSA) Surveillance Report 2010 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Health Authority Updated:
More informationAminoglycoside-resistant enterococci
Aminoglycoside-resistant enterococci M. J. BASKER, B. SLOCOMBE, AND R. SUTHERLAND From Beecham Pharmaceuticals Research Division, Brockham Park, Betchworth, Surrey J. clin. Path., 1977, 30, 375-380 SUMMARY
More informationIdentification of vancomycin-resistant enterococci clones and inter-hospital spread during an outbreak in Taiwan
Lee et al. BMC Infectious Diseases 2013, 13:163 RESEARCH ARTICLE Open Access Identification of vancomycin-resistant enterococci clones and inter-hospital spread during an outbreak in Taiwan Sai-Cheong
More informationPlease distribute a copy of this information to each provider in your organization.
HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to
More informationBrief reports. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae
Journal of Antimicrobial Chemotherapy (1997) 40, 105 108 Brief reports JAC Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae Andreas Pikis a *, Jacob A. Donkersloot
More informationPreventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal
Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier
More informationNosocomial Bloodstream Infections: Organisms, Risk Factors, and Implications
S139 Nosocomial Bloodstream Infections: Organisms, Risk Factors, and Implications Adolf W. Karchmer Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
More informationEvaluation of the BIOGRAM Antimicrobial Susceptibility Test System
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 1985, p. 793-798 0095-1137/85/110793-06$02.00/0 Copyright 1985, American Society for Microbiology Vol. 22, No. 5 Evaluation of the BIOGRAM Antimicrobial Susceptibility
More informationManagement of Native Valve
Management of Native Valve Infective Endocarditis 2005 AHA 2015 Baddour LM, et al. Circulation. 2015;132(15):1435-86 2009 ESC 2015 Habib G, et al. Eur Heart J. 2015;36(44):3075-128 ESC 2015: Endocarditis
More informationNational Surveillance of Antimicrobial Resistance in Pseudomonas aeruginosa Isolates Obtained from Intensive Care Unit Patients from 1993 to 2002
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2004, p. 4606 4610 Vol. 48, No. 12 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.12.4606 4610.2004 Copyright 2004, American Society for Microbiology. All Rights
More informationReceived 15 October 2006/Returned for modification 20 December 2006/Accepted 15 February 2007
JOURNAL OF CLINICAL MICROBIOLOGY, May 2007, p. 1556 1560 Vol. 45, No. 5 0095-1137/07/$08.00 0 doi:10.1128/jcm.02116-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Evaluation
More informationHigh Level Gentamicin Resistance and Vancomycin Resistance in Enterococcus species at a tertiary care hospital in India
ISSN: 2347-3215 Volume 3 Number 10 (October-2015) pp. 276-280 www.ijcrar.com High Level Gentamicin Resistance and Vancomycin Resistance in Enterococcus species at a tertiary care hospital in India Sangram
More informationDetection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran
Letter to the Editor Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran Mohammad Rahbar, PhD; Massoud Hajia, PhD
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationPILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 1996
PILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 996 November 996 by Maggie Brett Antibiotic Reference Laboratory ESR Communicable Disease Centre Porirua CONTENTS Page SUMMARY
More informationFailure of Cloxacillin in a Patient with BORSA Endocarditis ACCEPTED
JCM Accepts, published online ahead of print on 30 December 2008 J. Clin. Microbiol. doi:10.1128/jcm.00571-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationRisk Factors for Persistent MRSA Colonization in Children with Multiple Intensive Care Unit Admissions
University of Massachusetts Amherst From the SelectedWorks of Nicholas G Reich July, 2013 Risk Factors for Persistent MRSA Colonization in Children with Multiple Intensive Care Unit Admissions Victor O.
More information6. STORAGE INSTRUCTIONS
VRESelect 63751 A selective and differential chromogenic medium for the qualitative detection of gastrointestinal colonization of vancomycin-resistant Enterococcus faecium () and vancomycin-resistant Enterococcus
More informationAntibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco
Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationImpact of a Standardized Protocol to Address Outbreak of Methicillin-resistant
Impact of a Standardized Protocol to Address Outbreak of Methicillin-resistant Staphylococcus Aureus Skin Infections at a large, urban County Jail System Earl J. Goldstein, MD* Gladys Hradecky, RN* Gary
More informationChristiane Gaudreau* and Huguette Gilbert
Journal of Antimicrobial Chemotherapy (1997) 39, 707 712 JAC Comparison of disc diffusion and agar dilution methods for antibiotic susceptibility testing of Campylobacter jejuni subsp. jejuni and Campylobacter
More informationGram-positive bacteria: spread and antimicrobial resistance in university and community hospitals in the USA
Journal of Antimicrobial Chemotherapy (1988) 21, Suppl. C, 49-55 Gram-positive bacteria: spread and antimicrobial resistance in university and community hospitals in the USA John E. McGowan, Jr Department
More informationمادة االدوية المرحلة الثالثة م. غدير حاتم محمد
م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 1 Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease. Antimicrobial drugs:
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationOther Enterobacteriaceae
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 50: Other Enterobacteriaceae Author Kalisvar Marimuthu, MD Chapter Editor Michelle Doll, MD, MPH Topic Outline Topic outline - Key Issues Known
More informationDetection of Methicillin Resistant Strains of Staphylococcus aureus Using Phenotypic and Genotypic Methods in a Tertiary Care Hospital
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 7 (2017) pp. 4008-4014 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.607.415
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationAntibiotic-Resistant Bacteria in Surveillance Stool Cultures of
ANTIMICROBIAI AGENTS AND CHEMOTHERAPY, Sept. 1986, p. 435-439 0066-4804/86/090435-05$0)2.00/0 Copyright 1986. American Society for Microbiology Vol. 30, No. 3 Antibiotic-Resistant Bacteria in Surveillance
More informationFM - Male, 38YO. MRSA nasal swab (+) Due to positive MRSA nasal swab test, patient will be continued on Vancomycin 1500mg IV q12 for MRSA treatment...
Jillian O Keefe Doctor of Pharmacy Candidate 2016 September 15, 2015 FM - Male, 38YO HPI: Previously healthy male presents to ED febrile (102F) and in moderate distress ~2 weeks after getting a tattoo
More informationAntimicrobial stewardship in managing septic patients
Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest
More informationMulti-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version
Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED 2018 Printed copies must not be considered the definitive version DOCUMENT CONTROL POLICY NO. IC-122 Policy Group Infection Control
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationempirical therapy of febrile neutropenia in paediatric cancer patients
Original Article Singapore Med.1 2007, 48 (7) : 615 Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients Hamidah A, Lim Y S, Zulkifli S Z, Zarina
More informationAn evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage
Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. C, 1-7 An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage J. J. Muscato",
More informationStudy of High Level Aminoglycoside Resistance among Enterococci in a Tertiary Care Centre, Navi Mumbai, India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 1612-1620 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.186
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationTrends in Susceptibility of Vancomycin-resistant Enterococcus. faecium to Tigecycline, Daptomycin, and Linezolid and
AAC Accepts, published online ahead of print on 9 April 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.00533-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationSuitability of Antibiotic Treatment for CAP (CAPTIME) The duration of antibiotic treatment in community acquired pneumonia (CAP)
STUDY PROTOCOL Suitability of Antibiotic Treatment for CAP (CAPTIME) Purpose The duration of antibiotic treatment in community acquired pneumonia (CAP) lasts about 9 10 days, and is determined empirically.
More informationIncidence and outcome of vancomycin-resistant enterococcal bacteremia following autologous peripheral blood stem cell transplantation
(2000) 25, 147 152 2000 Macmillan Publishers Ltd All rights reserved 0268 3369/00 $15.00 www.nature.com/bmt Incidence and outcome of vancomycin-resistant enterococcal bacteremia following autologous peripheral
More information11-ID-10. Committee: Infectious Disease. Title: Creation of a National Campylobacteriosis Case Definition
11-ID-10 Committee: Infectious Disease Title: Creation of a National Campylobacteriosis Case Definition I. Statement of the Problem Although campylobacteriosis is not nationally-notifiable, it is a disease
More informationSUPPLEMENT ARTICLE. Donald E. Low, 1 Nathan Keller, 2 Alfonso Barth, 3 and Ronald N. Jones 4
SUPPLEMENT ARTICLE Clinical Prevalence, Antimicrobial Susceptibility, and Geographic Resistance Patterns of Enterococci: Results from the SENTRY Antimicrobial Surveillance Program, 1997 1999 Donald E.
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationActive Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply.
Impact of routine surgical ward and intensive care unit admission surveillance cultures on hospital-wide nosocomial methicillin-resistant Staphylococcus aureus infections in a university hospital: an interrupted
More informationEXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING
EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production
More informationBrief Report THE DEVELOPMENT OF VANCOMYCIN RESISTANCE IN A PATIENT WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTION
Brief Report THE DEVELOPMENT OF VANCOMYCIN RESISTANCE IN A PATIENT WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTION KRZYSZTOF SIERADZKI, PH.D., RICHARD B. ROBERTS, M.D., STUART W. HABER, M.D.,
More informationGeneral Approach to Infectious Diseases
General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor
More informationCipro for gram positive cocci in urine
Buscar... Cipro for gram positive cocci in urine 20-6-2017 Pneumonia can be generally defined as an infection of the lung parenchyma, in which consolidation of the affected part and a filling of the alveolar
More informationTRANSFERABLE RESISTANCE AND AMINOGLYCOSIDE-MODIFYING ENZYMES IN ENTEROCOCCI
J. MED. MICROBIOL. VOL.-20 (1985) 187-196 0 1985 The Pathological Society of Great Britain and Ireland TRANSFERABLE RESISTANCE AND AMINOGLYCOSIDE-MODIFYING ENZYMES IN ENTEROCOCCI H. Y. CHEN* AND J. D.
More informationIs Cefazolin Inferior to Nafcillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia?
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2011, p. 5122 5126 Vol. 55, No. 11 0066-4804/11/$12.00 doi:10.1128/aac.00485-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Is Cefazolin
More informationIs biocide resistance already a clinical problem?
Is biocide resistance already a clinical problem? Stephan Harbarth, MD MS University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland Important points Biocide resistance exists Antibiotic
More informationMEDICATION ADMINSITRATION: ANTIBIOTIC LOCK THERAPY GUIDELINE
MEDICATION ADMINSITRATION: ANTIBIOTIC LOCK THERAPY GUIDELINE I. PURPOSE Central venous catheters are an integral part in medical management for patients requiring long-term total parenteral nutrition,
More informationANTIMICROBIAL SUSCEPTIBILITY VANCOMYCIN RESISTANCE IN AN UNCOMMON ENTEROCOCCAL SPECIES
ENTEROCOCCAL SPECIES Sample ES-02 was a simulated blood culture isolate from a patient with symptoms of sepsis. Participants were asked to identify any potential pathogen and to perform susceptibility
More informationIn Vitro and In Vivo Activities of Clinafloxacin, CI-990 (PD ), and PD versus Enterococci
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1995, p. 2123 2127 Vol. 39, No. 9 0066-4804/95/$04.00 0 Copyright 1995, American Society for Microbiology In Vitro and In Vivo Activities of Clinafloxacin,
More informationPhenotypic and Genotypic Characterization of Enterococci from Clinical Isolates in a Tertiary Care Hospital
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 7 (2017) pp. 1160-1173 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.607.141
More informationPerformance Information. Vet use only
Performance Information Vet use only Performance of plates read manually was measured in three sites. Each centre tested Enterobacteriaceae, streptococci, staphylococci and pseudomonas-like organisms.
More informationJasmine M. Chaitram, 1,2 * Laura A. Jevitt, 1,2 Sara Lary, 1,2 Fred C. Tenover, 1,2 and The WHO Antimicrobial Resistance Group 3,4
JOURNAL OF CLINICAL MICROBIOLOGY, June 2003, p. 2372 2377 Vol. 41, No. 6 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.6.2372 2377.2003 The World Health Organization s External Quality Assurance System Proficiency
More informationGUIDE TO INFECTION CONTROL IN THE HOSPITAL. Enterococcal Species
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 44 Enterococcal Species Authors Jacob Pierce, MD, Michael Edmond, MD, MPH, MPA Michael P. Stevens, MD, MPH Chapter Editor Victor D. Rosenthal, MD, CIC,
More informationAntibiotic resistance and the human-animal interface: Public health concerns
Antibiotic resistance and the human-animal interface: Public health concerns Antibiotic Use and Resistance Moving forward through shared stewardship National Institute for Animal Agriculture Atlanta, Georgia
More informationLINEE GUIDA: VALORI E LIMITI
Ferrara 28 novembre 2014 LINEE GUIDA: VALORI E LIMITI Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi EVIDENCE BIASED GERIATRIC MEDICINE Older patients with comorbid conditions
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationReceived 8 April 2012; received in revised form 15 December 2012; accepted 28 December 2012
Journal of Infection and Public Health (2013) 6, 216 221 Antimicrobial agent prescription patterns for chemotherapy-induced febrile neutropenia in patients with hematological malignancies at Sultan Qaboos
More informationAntimicrobial Resistance Strains
Antimicrobial Resistance Strains Microbiologics offers a wide range of strains with characterized antimicrobial resistance mechanisms including: Extended-Spectrum β-lactamases (ESBLs) Carbapenamases Vancomycin-Resistant
More informationBurn Infection & Laboratory Diagnosis
Burn Infection & Laboratory Diagnosis Introduction Burns are one the most common forms of trauma. 2 million fires each years 1.2 million people with burn injuries 100000 hospitalization 5000 patients die
More informationApproval Signature: Original signed by Dr. Michel Tetreault Date of Approval: July Review Date: July 2017
WRHA Infection Prevention and Control Program Operational Directives Admission Screening for Antibiotic Resistant Organisms (AROs): Methicillin Resistant Staphylococcus aureus (MRSA) and Vancomycin Resistant
More informationamoxycillin/clavulanate vs placebo in the prevention of infection after animal
Archives of Emergency Medicine, 1989, 6, 251-256 A comparative double blind study of amoxycillin/clavulanate vs placebo in the prevention of infection after animal bites P. H. BRAKENBURY & C. MUWANGA Accident
More informationOriginal Article. Hossein Khalili a*, Rasool Soltani b, Sorrosh Negahban c, Alireza Abdollahi d and Keirollah Gholami e.
Iranian Journal of Pharmaceutical Research (22), (2): 559-563 Received: January 2 Accepted: June 2 Copyright 22 by School of Pharmacy Shaheed Beheshti University of Medical Sciences and Health Services
More informationCiprofloxacin, Enoxacin, and Ofloxacin against Aerobic and
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1988, p. 1143-1148 Vol., No. 8 0066-4804/88/081143-06$00/0 Copyright 1988, American Society for Microbiology Comparative Activities of, Amoxicillin-Clavulanic
More information